fda
Unplanned entry points, access routes blamed
FDA 周一表示,GLP-1 药物生产商须在产品标签上增加一项可能导致突然失明的警示。被称为非动脉炎性前部缺血性视神经病变(nonarteritic anterior ischemic optic neuropathy,NAION)的眼部疾病会影响视神经——负责将信号从眼睛传输至大脑的神经。当流向视神经的血液减少或受阻…
President Donald Trump's FDA pick, Heidi Overton, saw her nomination pulled one day before a Senate committee vote, a White House official confirmed.
ABD Gıda ve İlaç Dairesi (FDA), İsviçreli ilaç üreticisi Roche'un geliştirdiği Wilserdly adlı yeni meme kanseri ilacına pazartesi günü onay verdi. Giredestrant …
Haven't you heard? Myke had COVID.
The risk appears small and data is mixed, but FDA wants patients to be aware.
The data on which the FDA’s warning is based suggests a real but low risk of NAION for people taking GLP-1 medications.
In July 2026 the committee voted 8-6 to expand access to six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
(摘要暂无, 请查看原文)





